What is Pemvidutide and what makes it promising?

Pemvidutide (ALT-801) is a dual GLP-1/Glucagon receptor agonist developed by Altimmune. It shows particular promise for treating both obesity and MASH (metabolic dysfunction-associated steatohepatitis), addressing multiple conditions simultaneously.

How is Pemvidutide dosed?

In clinical trials, Pemvidutide is administered once weekly subcutaneously at doses of 1.2mg, 1.8mg, or 2.4mg. The titration schedule typically starts at 1.2mg with increases every 4 weeks based on tolerability.

What results has Pemvidutide shown in trials?

Phase 2 trials showed significant weight loss and improvements in liver fat, liver enzymes, and metabolic markers. The glucagon component appears particularly beneficial for liver health outcomes.

What is Pemvidutide development status?

Pemvidutide is in Phase 2 clinical trials for obesity and MASH. Altimmune is advancing the program with plans for Phase 3 trials. It represents one of several promising GLP-1/Glucagon dual agonists in development.

Precision Tool

Pemvidutide Dosage Calculator

Calculate the exact injection volume for your Pemvidutide dose. A promising dual agonist for metabolic and liver health.

Input Values

Peptide Vial Size

Total peptide in your vial

Bacteriostatic Water

Amount of BAC water added

Desired Dose

Your target dose per injection

Results

Concentration

2.50 mg/mL

Volume to Inject

0.480 mL

Insulin Syringe

48.0 units

on a 100-unit (1mL) syringe

Total Doses Per Vial

4 doses

Draw to the 48.0 unit mark on your insulin syringe to get exactly 1.2mg of peptide.

Order Research Peptides for Sale

USA-Manufactured, Third Party Tested Peptides
GMP USA Manufactured
Fast Global Shipping
Dedicated Support

Use code PEPTIDEIQ for 15% off any order

Shop Now

Clinical Dosing Guidelines

Product	Indication	Starting Dose	Max Dose
Pemvidutide (ALT-801)	Obesity/MASH (Phase 2)	1.2mg weekly	2.4mg weekly

Titration Schedule

12+ weeks typical

Current Selection

Week 1-4 — 1.2mg

Titration schedules may vary. Always follow your clinician's guidance.

Pemvidutide targets both GLP-1 and glucagon receptors.

Shows promise for both weight loss and MASH/fatty liver.

Inject once weekly subcutaneously.

Currently in Phase 2 clinical trials (Altimmune).

Frequently Asked Questions

See all GLP-1 medications compared

Our comprehensive reference guide covers every GLP-1 agonist — from approved blockbusters like semaglutide to next-gen candidates in clinical trials. Compare efficacy, side effects, cost, and delivery routes.

Read the Full Guide

Stay Updated

Get the latest peptide research and updates

No spam, unsubscribe anytime